BioSpace News Archive

Data update for ongoing ACTengine® IMA200 clinical trial seriesdemonstratedfirst anti-tumor activity in heavily pre-treated solid cancer patients during early phases of dose escalation

- Partnership between University of Pennsylvania Gene Therapy Program, James Wilson, M.D., Ph.D., Tachi Yamada, M.D., and Temasek - US$200 million financing commitment from Temasek to fund development of next-generation gene therapy companies with Penn’s Gene Therapy Program

Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases related to chronic glucose imbalance, today announced the addition of Quan Dong Nguyen, MD, MSc, FAAO, FARVO to its Scientific Advisory Board.

Alex Cadotte, PhD, Former U.S. Food & Drug Administration (FDA) Team Lead for Imaging Software and Division Lead for Software and Digital Health joins MCRA as Associate Director, Software & Digital Health.

Umoja Biopharma, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Irena Melnikova , Ph.D., as Chief Financial Officer.

Centene Corporation (NYSE: CNC) today announced its support for National Mental Health Month through a number of initiatives that empower providers and individuals to address behavioral health challenges

Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atlas Venture, Mission BioCapital and Foundation Fighting Blindness

Elpis Biopharmaceuticals , a biopharmaceutical company developing next generation multifunctional immunotherapies to transform cancer treatment, today announced the appointment of Dennis Benjamin, Ph.D., and Rakesh Jain, Ph.D., to the Scientific Advisory Board.

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Agenus executives will conduct a conference call to discuss the global licensing agreement between Agenus and Bristol Myers Squibb at 8:30 a.m. ET today.

Bristol-Myers Squibb Company (NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target.